Fort Sheridan Advisors LLC Grows Stock Holdings in Pfizer Inc. $PFE

Fort Sheridan Advisors LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 28.5% during the second quarter, HoldingsChannel.com reports. The firm owned 116,914 shares of the biopharmaceutical company’s stock after purchasing an additional 25,948 shares during the quarter. Fort Sheridan Advisors LLC’s holdings in Pfizer were worth $2,834,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the 1st quarter valued at about $27,000. Curio Wealth LLC lifted its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the second quarter valued at approximately $29,000. Finally, Evelyn Partners Asset Management Ltd bought a new position in Pfizer in the 2nd quarter valued at approximately $33,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.31 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $143.88 billion, a PE ratio of 13.46, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The firm’s 50 day moving average price is $25.03 and its 200-day moving average price is $24.62. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 7th were given a dividend of $0.43 per share. The ex-dividend date was Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s payout ratio is 100.00%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research analyst reports. Guggenheim lifted their target price on Pfizer from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, November 24th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Morgan Stanley lowered their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.39.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.